Literature DB >> 23074530

Application of the Ontario Diabetes Economic Model (ODEM) to Determine the Cost-effectiveness and Budget Impact of Selected Type 2 Diabetes Interventions in Ontario.

.   

Abstract

Entities:  

Year:  2009        PMID： 23074530      PMCID： PMC3377539     

Source DB:  PubMed          Journal:  Ont Health Technol Assess Ser        ISSN： 1915-7398


× No keyword cloud information.
  11 in total

1.  Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005: a population-based study.

Authors:  Lorraine L Lipscombe; Janet E Hux
Journal:  Lancet       Date:  2007-03-03       Impact factor: 79.321

2.  Dosage effects of diabetes self-management education for Mexican Americans: the Starr County Border Health Initiative.

Authors:  Sharon A Brown; Shelley A Blozis; Kamiar Kouzekanani; Alexandra A Garcia; Maria Winchell; Craig L Hanis
Journal:  Diabetes Care       Date:  2005-03       Impact factor: 19.112

3.  Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Introduction.

Authors:  Alice Y Y Cheng
Journal:  Can J Diabetes       Date:  2013-03-26       Impact factor: 4.190

4.  Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors.

Authors:  C Daousi; I F Casson; G V Gill; I A MacFarlane; J P H Wilding; J H Pinkney
Journal:  Postgrad Med J       Date:  2006-04       Impact factor: 2.401

5.  A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes.

Authors:  William H Herman; Liza L Ilag; Susan L Johnson; Catherine L Martin; Joyce Sinding; Abdulaziz Al Harthi; Cynthia D Plunkett; Frankie B LaPorte; Ray Burke; Morton B Brown; Jeffery B Halter; Philip Raskin
Journal:  Diabetes Care       Date:  2005-07       Impact factor: 19.112

6.  A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68).

Authors:  P M Clarke; A M Gray; A Briggs; A J Farmer; P Fenn; R J Stevens; D R Matthews; I M Stratton; R R Holman
Journal:  Diabetologia       Date:  2004-10-27       Impact factor: 10.122

7.  Spanish diabetes self-management with and without automated telephone reinforcement: two randomized trials.

Authors:  Kate Lorig; Philip L Ritter; Frank Villa; John D Piette
Journal:  Diabetes Care       Date:  2007-12-20       Impact factor: 19.112

8.  Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study.

Authors:  Philip Raskin; Bruce W Bode; Jennifer B Marks; Irl B Hirsch; Richard L Weinstein; Janet B McGill; Gregory E Peterson; Sunder R Mudaliar; Rickey R Reinhardt
Journal:  Diabetes Care       Date:  2003-09       Impact factor: 19.112

9.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

10.  Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report.

Authors:  Carol E Koro; Steven J Bowlin; Nancy Bourgeois; Donald O Fedder
Journal:  Diabetes Care       Date:  2004-01       Impact factor: 19.112
View more
  2 in total

Review 1.  Gap Between Evidence and Patient Access: Policy Implications for Bariatric and Metabolic Surgery in the Treatment of Obesity and its Complications.

Authors:  Amarpreet S Chawla; Chia-Wen Hsiao; Martha C Romney; Ricardo Cohen; Francesco Rubino; Philip Schauer; Pierre Cremieux
Journal:  Pharmacoeconomics       Date:  2015-07       Impact factor: 4.981

2.  Prediction of mortality and macrovascular complications in type 2 diabetes: validation of the UKPDS Outcomes Model in the Casale Monferrato Survey, Italy.

Authors:  E Pagano; A Gray; R Rosato; G Gruden; P Cavallo Perin; F Merletti; G Bruno
Journal:  Diabetologia       Date:  2013-05-17       Impact factor: 10.122
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.